Home › Funds › Avidity Partners Management LP › AKTS
Avidity Partners Management LP position in AKTS
AKTIS ONCOLOGY INC · Health Care
Avidity Partners Management LP reported holding 484,200 shares of AKTS (AKTIS ONCOLOGY INC) in its Q2 2026 13F filing — a position valued at US$15.6M, representing 2.50% of its reported portfolio and ranking #7 among its reported holdings. Avidity Partners Management LP has disclosed AKTS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Avidity Partners Management LP's AKTS position evolved
Avidity Partners Management LP first disclosed a stake in AKTS in Q1 2026 at 468,566 shares (US$8.4M). The position peaked in Q2 2026 at 484,200 shares, worth US$15.6M. Across 2 filings, Avidity Partners Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 484,200 shares valued at US$15.6M — an increase of 15,634 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 468.57K | $8.38M | New |
| Q2 2026 | 484.20K | $15.61M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AKTS and 13F data
AKTS (AKTIS ONCOLOGY INC) is a Health Care company. 121 other funds we track also report a position in AKTS — the largest reported positions include MPM BioImpact LLC (US$155.9M), EcoR1 Capital, LLC (US$155.5M), Blue Owl Capital Holdings LP (US$99.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AKTS
- MPM BioImpact LLC 4.84M sh · $155.86M · Q2 2026
- EcoR1 Capital, LLC 4.82M sh · $155.49M · Q2 2026
- Blue Owl Capital Holdings LP 3.07M sh · $98.95M · Q2 2026
- RTW INVESTMENTS, LP 1.59M sh · $51.31M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 1.31M sh · $42.36M · Q2 2026
- BAKER BROS. ADVISORS LP 996.35K sh · $32.11M · Q2 2026
- Octagon Capital Advisors LP 960.85K sh · $30.97M · Q2 2026
- Merck & Co., Inc. 952.84K sh · $30.71M · Q2 2026
- TCG Crossover Management, LLC 696.56K sh · $22.45M · Q2 2026
- a16z Capital Management, L.L.C. 415.00K sh · $13.38M · Q2 2026
More on Avidity Partners Management LP
FAQ
How long has Avidity Partners Management LP held AKTS?
Avidity Partners Management LP has disclosed AKTS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Avidity Partners Management LP's current position in AKTS?
As of Q2 2026, Avidity Partners Management LP holds 484.20K shares of AKTS (AKTIS ONCOLOGY INC), valued at $15.61M, representing 2.50% of its reported portfolio and ranking #7.
Has Avidity Partners Management LP been buying or selling AKTS?
In the latest 13F filing (Q2 2026), Avidity Partners Management LP increased its position in AKTS. The position peaked in Q2 2026 at 484.20K shares.
Which other funds hold AKTS?
Other major institutional holders of AKTS include MPM BioImpact LLC, EcoR1 Capital, LLC, Blue Owl Capital Holdings LP, among 121 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.